Skip to main content

Table 1 Characteristics of patients with CRC stratified by BO

From: A nomogram for predicting bowel obstruction in preoperative colorectal cancer patients with clinical characteristics

Patient characteristics

Overall (N%)

No BO (N%)

BO (N%)

Gender

 Male

5293 (44.8%)

3831 (44.0%)

1462 (47.1%)

 Female

6521 (55.2%)

4879 (56.0%)

1642 (52.9%)

Age at diagnosis, years

 66–70

1525 (12.9%)

966 (11.1%)

559 (18.0%)

 71–75

1975 (16.7%)

1296 (14.9%)

679 (21.9%)

 76–80

2342 (19.8%)

1617 (18.6%)

725 (23.4%)

 > 80

5972 (50.6%)

4831 (55.5%)

1141 (36.8%)

Race

 White

9421 (79.7%)

6945 (79.7%)

2476 (79.8%)

 Black

1566 (13.3%)

1185 (13.6%)

381 (12.3%)

 Asian

372 (3.1%)

244 (2.8%)

128 (4.1%)

 Other

455 (3.9%)

336 (3.9%)

119 (3.8%)

Marital status

 Single + separated

1358 (11.5%)

1023 (11.7%)

335 (10.8%)

 Married

4441 (37.6%)

3015 (34.6%)

1426 (45.9%)

 Divorced + widowed

5296 (44.8%)

4073 (46.8%)

1223 (39.4%)

 Other

719 (6.1%)

599 (6.9%)

120 (3.9%)

Residence location*

 Big metro

6750 (57.2%)

4869 (55.9%)

1881 (60.6%)

 Metro or urban

3814 (32.3%)

2886 (33.1%)

928 (29.9%)

 Less urban or rural

1247 (10.6%)

952 (10.9%)

295 (9.5%)

Median household income

 1st quartile

2781 (23.5%)

2094 (24.0%)

687 (22.1%)

 2nd quartile

2791 (23.6%)

2058 (23.6%)

733 (23.6%)

 3rd quartile

2786 (23.6%)

2037 (23.4%)

749 (24.1%)

 4th quartile

2791 (23.6%)

2015 (23.1%)

776 (25.0%)

 Unknown

665 (5.6%)

506 (5.8%)

159 (5.1%)

Level of education

 1st quartile

2770 (23.4%)

2032 (23.3%)

738 (23.8%)

 2nd quartile

2817 (23.8%)

2068 (23.7%)

749 (24.1%)

 3rd quartile

2798 (23.7%)

2061 (23.7%)

737 (23.7%)

 4th quartile

2762 (23.4%)

2043 (23.5%)

719 (23.2%)

 Unknown

667 (5.6%)

506 (5.8%)

161 (5.2%)

Year of diagnosis

 1992–1996

1228 (10.4%)

758 (8.7%)

470 (15.1%)

 1997–2001

1999 (16.9%)

1478 (17.0%)

521 (16.8%)

 2002–2005

3752 (31.8%)

2796 (32.1%)

956 (30.8%)

 2006–2009

4835 (40.9%)

3678 (42.2%)

1157 (37.3%)

Tumor characteristics

 T category

  Tis

595 (5.0%)

491 (5.6%)

104 (3.4%)

  T1

2054 (17.4%)

1662 (19.1%)

392 (12.6%)

  T2

307 (2.6%)

126 (1.4%)

181 (5.8%)

  T3

1647 (13.9%)

596 (6.8%)

1051 (33.9%)

  T4a

161 (1.4%)

35 (0.4%)

126 (4.1%)

  T4b

717 (6.1%)

457 (5.2%)

260 (8.4%)

  Unknown

6333 (53.6%)

5343 (61.3%)

990 (31.9%)

 M category

  M0

2475 (20.9%)

1686 (19.4%)

789 (25.4%)

  M1

3311 (28.0%)

2684 (30.8%)

627 (20.2%)

  Unknown

6028 (51.0%)

4340 (49.8%)

1688 (54.4%)

 Primary tumor site

  Rectum

4674 (39.6%)

3666 (42.1%)

1008 (32.5%)

  Left-sided colon

2624 (22.2%)

1648 (18.9%)

976 (31.4%)

  Right-sided colon

4516 (38.2%)

3396 (39.0%)

1120 (36.1%)

 Histologic type

  Adenocarcinoma

11,200 (94.8%)

8375 (96.2%)

2825 (91.0%)

  Mucinous carcinoma

523 (4.4%)

281 (3.2%)

242 (7.8%)

  Signet-ring cell carcinoma

91 (0.8%)

54 (0.6%)

37 (1.2%)

 Histologic grade

  Well

724 (6.1%)

509 (5.8%)

215 (6.9%)

  Moderate

5011 (42.4%)

3327 (38.2%)

1684 (54.3%)

  Poor

1488 (12.6%)

973 (11.2%)

515 (16.6%)

  Undifferentiated

96 (0.8%)

69 (0.8%)

27 (0.9%)

  Unknown

4495 (38.0%)

3832 (44.0%)

663 (21.4%)

 Tumor size

  < 35 mm

1134 (9.6%)

693 (8.0%)

441 (14.2%)

  35–50 mm

1039 (8.8%)

522 (6.0%)

517 (16.7%)

  50–65 mm

1241 (10.5%)

760 (8.7%)

481 (15.5%)

  ≥ 65 mm

1103 (9.3%)

639 (7.3%)

464 (14.9%)

  Unknown

7297 (61.8%)

6096 (70.0%)

1201 (38.7%)

Presenting features

 HCC risk score

  1st quartile

2955 (25.0%)

2232 (25.6%)

723 (23.3%)

  2nd quartile

2980 (25.2%)

2079 (23.9%)

901 (29.0%)

  3rd quartile

2917 (24.7%)

2089 (24.0%)

828 (26.7%)

  4th quartile

2962 (25.1%)

2310 (26.5%)

652 (21.0%)

 History of alcoholism

  No

11,390 (96.4%)

8369 (96.1%)

3021 (97.3%)

  Yes

424 (3.6%)

341 (3.9%)

83 (2.7%)

 Tobacco

  No

10,457 (88.5%)

7690 (88.3%)

2767 (89.1%)

  Yes

1357 (11.5%)

1020 (11.7%)

337 (10.9%)

 History of colorectal polyps

  No

10,459 (88.5%)

7710 (88.5%)

2749 (88.6%)

  Yes

1355 (11.5%)

1000 (11.5%)

355 (11.4%)

 Obesity

  No

10,916 (92.4%)

8045 (92.4%)

2871 (92.5%)

  Yes

898 (7.6%)

665 (7.6%)

233 (7.5%)

Treatment

 Chemotherapy

  Nonchemotherapy

9105 (77.1%)

6651 (76.4%)

2454 (79.1%)

  5-FU/capecitabine

1398 (11.8%)

1047 (12.0%)

351 (11.3%)

  FOLFOX/CapeOX

277 (2.3%)

213 (2.4%)

64 (2.1%)

  FOLFIRI/XELIRI

242 (2.0%)

186 (2.1%)

56 (1.8%)

  FOLFOX/CapeOX + bevacizumab

273 (2.3%)

227 (2.6%)

46 (1.5%)

  FOLFIRI/XELIRI + bevacizumab

42 (0.4%)

29 (0.3%)

13 (0.4%)

  Other

477 (4.0%)

357 (4.1%)

120 (3.9%)

 Radiotherapy

  No

9912 (83.9%)

7252 (83.3%)

2660 (85.7%)

  Yes

1902 (16.1%)

1458 (16.7%)

444 (14.3%)

Presenting symptoms

 Abdominal pain

  No

9091 (77.0%)

6773 (77.8%)

2318 (74.7%)

  Yes

2723 (23.0%)

1937 (22.2%)

786 (25.3%)

 Abdominal mass

  No

11,414 (96.6%)

8431 (96.8%)

2983 (96.1%)

  Yes

400 (3.4%)

279 (3.2%)

121 (3.9%)

 Abdominal distension

  No

11,624 (98.4%)

8574 (98.4%)

3050 (98.3%)

  Yes

190 (1.6%)

136 (1.6%)

54 (1.7%)

 Ascites

  No

11,712 (99.1%)

8630 (99.1%)

3082 (99.3%)

  Yes

102 (0.9%)

80 (0.9%)

22 (0.7%)

 Anemia

  No

10,688 (90.5%)

7803 (89.6%)

2885 (92.9%)

  Yes

1126 (9.5%)

907 (10.4%)

219 (7.1%)

 Nutritional deficiency

  No

11,152 (94.4%)

8153 (93.6%)

2999 (96.6%)

  Yes

662 (5.6%)

557 (6.4%)

105 (3.4%)

 Cachexia

  No

11,742 (99.4%)

8649 (99.3%)

3093 (99.6%)

  Yes

72 (0.6%)

61 (0.7%)

11 (0.4%)

 Change of bowel habits

  No

11,394 (96.4%)

8395 (96.4%)

2999 (96.6%)

  Yes

420 (3.6%)

315 (3.6%)

105 (3.4%)

 Change of character of stool

  No

9536 (80.7%)

7064 (81.1%)

2472 (79.6%)

  Yes

2278 (19.3%)

1646 (18.9%)

632 (20.4%)

 Hemorrhage

  No

9366 (79.3%)

6859 (78.7%)

2507 (80.8%)

  Yes

2448 (20.7%)

1851 (21.3%)

597 (19.2%)

 Diarrhea

  No

10,899 (92.3%)

8022 (92.1%)

2877 (92.7%)

  Yes

915 (7.7%)

688 (7.9%)

227 (7.3%)

 Gatism

  No

11,728 (99.3%)

8640 (99.2%)

3088 (99.5%)

  Yes

86 (0.7%)

70 (0.8%)

16 (0.5%)

 Loss of appetite

  No

11,569 (97.9%)

8501 (97.6%)

3068 (98.8%)

  Yes

245 (2.1%)

209 (2.4%)

36 (1.2%)

 Vomiting

  No

11,066 (93.7%)

8142 (93.5%)

2924 (94.2%)

  Yes

748 (6.3%)

568 (6.5%)

180 (5.8%)

 Weight loss

  No

10,672 (90.3%)

7838 (90.0%)

2834 (91.3%)

  Yes

1142 (9.7%)

872 (10.0%)

270 (8.7%)

  1. Abbreviations: CRC colorectal cancer, BO bowel obstruction, HCC the Centers for Medicare and Medicaid Service’s Hierarchical Condition Category, 5-FU 5-fluorouracil, FOLFOX 5-FU + oxaliplatin, CapeOX capecitabine + oxaliplatin, FOLFIRI 5-FU + irinotecan, and XELIRI capecitabine + irinotecan. *variable has missing data